Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $61.0 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 53.25% to $75.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $75.2 million, marking a year-over-year increase of 53.25%. This contributed to the annual value of $61.0 million for FY2024, which is 26.99% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Shares Outstanding (Diluted Average) of $61.0 million as of FY2024, which was up 26.99% from $48.0 million recorded in FY2023.
  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $61.0 million during FY2024, with a 5-year trough of $46.6 million in FY2022.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $48.0 million (2023), whereas its average is $51.9 million.
  • Data for Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY rose of 26.99% (in 2024) over the last 5 years.
  • Over the past 3 years, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $46.6 million in 2022, then grew by 3.16% to $48.0 million in 2023, then climbed by 26.99% to $61.0 million in 2024.